Diagnostic composition and kit for renal cell carcinoma

Abstract

Disclosed herein are a composition and a kit for diagnosing renal cell carcinoma. The composition and kit employ, as a renal cell carcinoma marker, nicotinamide N-methyltransferase, L-plastin, secretagogin, NM23A, CapG, which is an actin regulatory protein, and/or C4a anaphylatoxin.

1. A method for diagnosing renal cell carcinoma in a patient comprising steps of:
 preparing a composition containing a binding molecule that specifically binds NNMT protein; 
 contacting the composition with a biological sample from a patient to measure expression level of NNMT protein, wherein the biological sample is a sample selected from the group consisting of a blood sample, a serum sample and a plasma sample; and 
 comparing the expression level of NNMT protein in the biological sample from the patient with the expression level of NNMT protein in a corresponding biological sample from a normal individual; and 
 classifying a patient with an elevated expression level of NNMT protein as having renal cell carcinoma. 
 
     
     
       2. The method according to  claim 1 , wherein the binding molecule is an antibody and the antibody is one or more selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a multispecific antibody, a fragment of the antibody, a recombinant antibody, and a chemically modified antibody. 
     
     
       3. The method according to  claim 2 , wherein the antibody fragment is Fab, F(ab′) 2 , scFv, Fv, Fab/c, a digestion product of an antibody using a proteolytic enzyme, or an antibody prepared using a recombinant DNA technique. 
     
     
       4. The method according to  claim 2 , wherein the antibody is a monoclonal antibody or a polyclonal antibody. 
     
     
       5. The method according to  claim 4 , wherein the monoclonal antibody is prepared using a method of producing a monoclonal antibody comprising immunizing a mammal with the renal cell carcinoma marker and collecting antibody-producing cells, fusing the antibody-producing cells with myeloma cells to establish a hybridoma, and obtaining the monoclonal antibody from the hybridoma. 
     
     
       6. The method according to  claim 5 , wherein the antibody-producing cells are splenocytes (spleen cells), lymph node cells, or peripheral blood cells. 
     
     
       7. The method according to  claim 5 , wherein the mammal is a rat, a mouse, a rabbit, or a monkey. 
     
     
       8. The method according to  claim 5 , wherein the myeloma cells are derived from an animal of the same species as the mammal, have drug selectivity, and cannot survive in an HAT selection medium supplemented with hypoxanthine, aminopterin and thymidine in a state of being not fused with splenocytes, but can survive in a state of being fused with splenocytes. 
     
     
       9. The method according to  claim 5 , wherein the renal cell carcinoma marker is a fragment of a full-length protein.